SecBot SecBot
PRESS-RELEASE ·Filed Nov 19, 2026

LSTA

Lisata Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed2d 22h ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

The reverse split is a technical measure to maintain Nasdaq listing, not a fundamental change. The larger risk is the overhang from the S-3 registration of ~350M shares for resale by former Marea stockholders and PIPE investors, which could pressure the stock post-split. Monitor trading volume and any insider selling patterns.

DirectionNeutral
Confidencehigh
Horizondays

Drugs in focus

LSTA drug pipeline →

MAR001/005

● Neutral Named in this press release
Impact
Phase
Phase 2b
Time to market
At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
Next catalyst
None dated

What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9100
T+0 close · Nov 19, 2026 · via day close
Latest settled
−1.22%
T+1 · $0.8989
Vs SPY
+2.42%
α at T+1
Next horizon
T+5
in 5d
  1. T+0 · Nov 19 $0.9100entry
  2. T+1 · 2d ago −1.22%α +2.42% · $0.8989
  3. T+5 · in 5d Pending
  4. T+20 · in 26d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lisata Therapeutics announced a 1-for-15 reverse stock split, effective November 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The split reduces outstanding shares from ~10.8M to ~0.7M and follows a recent S-3 shelf registration that registered ~350M shares for resale by selling stockholders, creating potential overhang.

Key Facts

  • Reverse stock split ratio of 1-for-15, effective November 23, 2026
  • Outstanding shares reduced from ~10.8M to ~0.7M
  • Stockholders approved the split at the November 9, 2026 annual meeting
  • No fractional shares will be issued; cash paid in lieu
  • S-3 shelf filed 7 days ago registers ~350M shares for resale by selling stockholders from the Marea acquisition and PIPE
  • Company will not receive proceeds from the S-3 resale

Financial Impact

Reduction in share count from ~10.8M to ~0.7M; no change in market cap or ownership percentages

share countstock price

Risk Factors

  • Potential selling pressure from S-3 registered shares (350M shares for resale)
  • Low market cap ($11M) and low liquidity amplify price moves
  • Reverse split alone does not address business fundamentals; clinical-stage pipeline with no approved products

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3406677

Track record

21 reports on LSTA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
  2. Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
  3. Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
  4. Nov 19, 20262d ago Press Release Neutral 4/10 Viewing Entry $0.9100 settles Feb 18
  5. Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
  6. Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
  8. Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
  9. Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
  10. Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
Showing 10 of 21

US Market Status

Market Closed · Opens Mon (26h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 19, 2026